Phase 3 Readout
GERN: Phase 3 Topline: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermed
October 13, 2026 · ipss. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 13, 2026
- Company
- GERON CORP (GERN)
- Drug
- ipss
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermed
- Company
- GERON CORP (GERN)
- Drug
- ipss
- Indication
- Myelodysplastic Syndromes